Compare · MTSR vs PFE
MTSR vs PFE
Side-by-side comparison of Metsera Inc. (MTSR) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTSR and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE carries a market cap of $304.95B.
- Over the past year, MTSR is up 254.8% and PFE is up 17.1% - MTSR leads by 237.6 points.
- PFE has hit the wire 10 times in the past 4 weeks while MTSR has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 6 for MTSR).
- Company
- Metsera Inc.
- Pfizer Inc.
- Price
- $70.53-0.32%
- $26.98+1.20%
- Market cap
- -
- $304.95B
- 1M return
- +33.65%
- -1.21%
- 1Y return
- +254.75%
- +17.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 0
- 10
- Recent ratings
- 6
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest MTSR
- SEC Form 15-12G filed by Metsera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.
- See Remark 1 Fmr Llc disposed of 2,233,460 shares (SEC Form 4)
- Director Arch Venture Partners Xii, Llc returned 26,816,808 shares to the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Metsera Inc.
- SEC Form SCHEDULE 13G filed by Metsera Inc.
- CHIEF LEGAL OFFICER Lang Matthew returned 12,500 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Berns Paul L returned 16,798,952 shares to the company, closing all direct ownership in the company (SEC Form 4)
- CHIEF MEDICAL OFFICER Marso Steven returned 17,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Large owner Population Health Partners Gp, Llc returned 12,767,462 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities